News

Oral cancer in now the 10th most common cancer in men as overall the incidence of the disease has risen by a third in the last decade, show new figures from Cancer Research UK.

A bill under which the government would have gained responsibility for repurposing off-patent medicines showing promise in unlicensed indications has failed to make it past its second reading in parliament. 

A subcutaneous formulation of GlaxoSmithKline’s Benlysta has hit targets in a Phase III trial involving patients with active, autoantibody-positive systemic lupus erythematosus.

London, UK-based PepTCell (trading as SEEK) is linking with the National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH), to jointly lead a human challenge study of its universal flu candidate, FLU-v.

The US Food and Drug Administration has approved Gilead’s Genvoya – which combines four medicines in a single pill – giving certain patients with HIV a new treatment option.

Merck & Co’s neuromuscular blockade antidote sugammadex has cleared a significant hurdle to market after winning backing from a panel of US regulatory advisors for the reversal for general anaesthesia.

AstraZeneca has unveiled plans to buy California-based ZS Pharma for $2.7 billion in a move that adds ballast to its cardiovascular and metabolic disease offering.

Entries from all over the world have been flowing in, testament to the commitment of clinical researchers to their continued professional development.

Health Enterprise East, a provider of business and innovation management services to the NHS and industry, has sold Northwood Medical Innovations to global pharma Allergan for an undisclosed amount.

The government’s case for seven-day working in primary care has taken another hit with a new batch of data suggesting that most patients don’t need weekend opening.

Sanofi has inked a licensing deal with South Korea’s Hanmi to beef up its research pipeline with a trio of investigational diabetes therapies.

The US has become the first country in the world to approve GlaxoSmithKline’s novel biologic Nucala, as an add-on maintenance therapy for a difficult-to-treat form of asthma.

Johnson & Johnson has announced that it is acquiring privately-held, clinical-stage biopharma Novira Therapeutics, but has kept financial details of the deal firmly under wraps.

Japanese drug giant Eisai has entered into a joint development programme with the Liverpool School of Tropical Medicine and the University of Liverpool for preclinical development of the novel antimalarial candidate E209.

The National Health Service could save tens of millions of pounds by switching to a new radiotherapy regime for patients with prostate cancer, suggest findings of a major clinical trial presented at the National Cancer Research Institute Cancer Conference in Liverpool this week.